Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
Cancer Vaccines01:30

Cancer Vaccines

251
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
251
Cancer Therapies02:49

Cancer Therapies

7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

731
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
731

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous carbon decoupling and peaking pathways across county types in hunan province: an integrated tapio-STIRPAT-scenario analysis.

Carbon balance and management·2026
Same author

Response of soil microbiomes to nano-zero-valent iron and biochar in Cr(VI)-contaminated soil remediation.

Ecotoxicology (London, England)·2026
Same author

How are pedestrian safety compromised under suppressed warning cyberattacks at a connected intersection? - Exploring vehicle-pedestrian interactions using a hidden markov model-based approach.

Accident; analysis and prevention·2026
Same author

A single-dose mRNA vaccine induces potent and long-lasting humoral and cellular immunity against the varicella-zoster virus in a murine model.

Frontiers in immunology·2026
Same author

Identification and Validation of NAC Transcription Factors Enhancing Phenolic Acid Production in <i>Perilla frutescens</i>.

Plants (Basel, Switzerland)·2026
Same author

Solar radiation differences drive karst sun and shade leaf carbon sink contribution shifts.

Carbon balance and management·2026

Related Experiment Video

Updated: May 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification.

Ningye Ma1, Jian Gao1, Xiaoao Pang1

  • 1Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|May 10, 2025
PubMed
Summary

Oncolytic viruses (OVs) show promise for cancer treatment by targeting tumors and stimulating immune responses. Pharmaceutical formulations are crucial for overcoming delivery challenges and improving the effectiveness of OV therapies for solid tumors.

Keywords:
Oncolytic viruses (OVs)Protective encapsulationSystemic deliveryTumor immunotherapy

More Related Videos

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.3K

Related Experiment Videos

Last Updated: May 13, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.4K
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
06:14

Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus

Published on: May 13, 2021

6.3K

Area of Science:

  • Oncology
  • Immunology
  • Pharmaceutical Sciences

Background:

  • Cancer remains a significant global health issue with limitations in traditional treatments.
  • Tumor immunotherapy, particularly oncolytic viruses (OVs), offers a promising approach by selectively targeting and destroying cancer cells.
  • Current OV therapies face delivery challenges, including intratumoral injection limitations, hindering widespread clinical application.

Purpose of the Study:

  • To review the critical role of pharmaceutical formulations in enhancing oncolytic virus (OV) therapy.
  • To outline recent advances in OV formulations for improved tumor targeting and delivery.
  • To discuss strategies for reducing adverse effects and boosting antitumor immunity with OV formulations.

Main Methods:

  • Review of current literature on oncolytic virus (OV) therapy and pharmaceutical formulations.
  • Analysis of strategies for enhancing tumor targeting and viral accumulation.
  • Evaluation of formulation approaches to improve OV delivery and efficacy.

Main Results:

  • Pharmaceutical formulations are key to overcoming major delivery challenges in OV therapy.
  • Optimized formulations can enhance tumor targeting, reduce adverse effects, and promote antitumor immunity.
  • Advanced formulation strategies are crucial for the clinical translation of OV therapies.

Conclusions:

  • Pharmaceutical formulations are essential for improving the therapeutic potential of oncolytic viruses (OVs).
  • Novel delivery systems and formulation strategies are needed to enhance OV efficacy and clinical applicability.
  • Further research into OV formulations will drive advancements in cancer immunotherapy.